Skip to main content
Quest Diagnostics

High-Resolution Monitoring of B Cell Isotype Switching for Immuno-Oncology Biomarker Discovery Using the Clinically Validated Quest Diagnostics IGH-LR Assay

AACR 2024

American Association for Cancer Research

San Diego, CA, April 5-10, 2024

Poster presentation: High-Resolution Monitoring of B Cell Isotype Switching for Immuno-Oncology Biomarker Discovery Using the Clinically Validated Quest Diagnostics IGH-LR Assay

Authors: Prathapam R, Champion K, Burkhardt A, Smith CL, Singh R, Looney T

Specialty: Oncology, Genetics

Related content

Audio Podcast
Optimize Oncology Care with Clinical Pathways
Publication
The path to a better biomarker application of a
Publication
Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology
Conference Presentation
Determining the Immune Landscape of Patients with B- and T-cell Malignancies Utilizing Whole Transcriptome RNA Sequencing and TRUST4

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.